Development of new therapeutic approaches for gastrointestinal disease through basic research focused on gastrointestinal cancer and liver cirrhosis

Recently, the development of new drugs and therapeutic strategies have made it possible to control disease status in many gastrointestinal（GI）diseases. However, GI cancer still accounts for half of the cancer deaths in Japan, and therefore, development of a new therapeutic approach is urgently required. On the other hand, new oral combination treatment has dramatically improved health outcomes for patients with hepatitis C. However, liver cirrhosis, the end-stage of every chronic liver disease still being the major risk factor for the development of hepatocellular carcinoma. Until now, the author has been involved in translational research focused on GI diseases with a particular focus on GI cancer and cirrhosis based on clinical（patient）needs. This review focused on the author’s research on new treatments approach and clinical trials, especially for GI cancer and cirrhosis and discussed the future directions of our study